abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

31 Jan 2017

Lydia Ramsey, Business Insider (UK)

USA: Diabetes patients sue Novo Nordisk, Sanofi, & Eli Lilly for alleged insulin price-fixing

"The makers of insulin are being accused of price-fixing in a class-action lawsuit", 30 Jan 2017

A lawsuit filed Monday alleges that the three companies that make insulin have been part of an "organized scheme to drive up prices at the expense of patients who need insulin drugs to live."...The complaint...details examples of patients who pay $900 a month for the drug...The suit alleges that the drug companies — Novo Nordisk, Sanofi, and Lilly — violate the Racketeer Influenced and Corrupt Organizations Act. “People living with diabetes are practically imprisoned under the price hikes and sadly are resorting to extreme measures to afford the medication they need to live,” Steve Berman, a managing partner at the legal firm representing the patients in the suit..."We strongly believe these allegations have no merit, and will defend against these claims," Sanofi said in a statement.  Lilly said..."...we adhere to the highest ethical standards."...Novo said in a statement..."We disagree with the allegations made against the company...At Novo Nordisk, we have a longstanding commitment to supporting patients’ access to our medicines."...